Full-scale business targeting treatment of tendon, ligament, and muscle injuries
[by Yu, Suin] L&C Bio, a company specializing in regenerative medicine for human tissue, announced on April 16 that it has secured a 슬롯사이트 추천 for its proprietary technology of ‘ultra-fine acellular dermis manufacturing method,’ a technology designed to be injected into damaged soft tissue regions.
The 슬롯사이트 추천 was granted three years and five months after the initial application in November 2021. It encompasses the manufacturing processes for ‘MegaFill Hiject’ and ‘Aesten Inject.’
The registered 슬롯사이트 추천 pertains to a manufacturing technology of ultra-fine acellular dermis in a form that can be discharged (expelling liquid, gas, or powder out of a machine or device) through a micro-diameter needle. This is achieved through an ultra-low temperature pulverization process that preserves the collagen content and structural integrity of the acellular dermis. The technology is notable for its ability to reduce patient discomfort by making it possible to inject into soft tissue using a micro-needle.
To enable the injection of 슬롯사이트 추천 dermis into the human body, it is essential to subject the material to a micro-processing technique to reduce its size. To minimize patient discomfort during injection, the processed material must be manufactured in a way that it can discharge even from a micro-diameter needle. However, the heat generated during the conventional micronization process can denature collagen, the primary component of 슬롯사이트 추천 dermis, thereby compromising its original functional properties, including tissue reinforcement through the activation of growth factors and cells.
The newly 슬롯사이트 추천ed technology is based on a three-step micronization process. The first step involves the physical crushing of the acellular dermis. In the second step, the material is frozen at an ultra-low temperature and further pulverized. The final step entails a sieve-based separation process using strong suction to obtain acellular dermis particles of uniform size. According to the company, this advanced process has improved productivity by increasing the yield of acellular dermis while reducing the overall processing time compared to conventional methods.
The micronized 슬롯사이트 추천 dermis, primarily composed of collagen, plays a key role in activating cells and growth factors in the body. It is applicable to a wide range of indications, including degenerative arthritis, cervical and spinal disc disorders, and plantar fasciitis. Its therapeutic purpose lies in promoting recovery and regeneration in various tissues, such as damaged muscles, biomembranes, ligaments, and cartilage.
Currently, ‘MegaFill Hiject’ and ‘Aesten Inject,’ developed using the 슬롯사이트 추천ed technology, activate cells and growth factors in the body and demonstrate excellent efficacy in the treatment of damaged tissues, including tendons, ligaments, and muscles, as well as in the regeneration of soft tissues. These products are widely used in frontline medical institutions.
With this acquisition of this 슬롯사이트 추천, L&C Bio intends to accelerate its sales and marketing efforts to promote the active clinical use of its products. The company noted that the 슬롯사이트 추천 will serve to protect the quality of its offerings and safeguard its proprietary, unique technology.
“Since our founding, we have evolved into one of Korea’s leading companies in the field of tissue engineering, driven by evidence-based joint research and development in close collaboration with some of the country’s top medical professionals,” stated Lee Whan Chul, CEO of L&C 슬롯사이트 추천. “Earlier this year, we received approval for ‘MegaDerm Plus’ from China’s National Medical Products Administration (NMPA), and full-scale commercialization in the Chinese market is set to begin in the second quarter. Building on this momentum, we will accelerate efforts to enhance corporate value and expand our global presence.”
L&C Bio currently operates three corporate research institutes, including L&C ES and the Global Medical Research Center, and remains dedicated to the development of innovative, next-generation products in each area of specialization. As of April 2025, the company has secured intellectual property rights through a total of 27 슬롯사이트 추천s (25 in Korea, 2 in the United States). Additionally, L&C Bio is actively pursuing additional intellectual property rights, with 50 슬롯사이트 추천 applications currently in progress (23 in Korea, 17 under the 슬롯사이트 추천 Cooperation Treaty [PCT], and 10 in the United States). The company has also published 78 SCI-indexed papers in collaboration with leading medical professionals, and this number is expected to exceed 100 within the year.